Phase 2 Lung Cancer Trial, Not Yet Recruiting NCT06554535 Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Not Yet Recruiting

NCT06554535
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 or older, of any sex.
  • People who have been diagnosed with extensive-stage small cell lung cancer (a specific type and stage of lung cancer), confirmed through laboratory testing of tissue or cell samples.
  • People who have not yet received any systemic (whole-body) treatment for this type and stage of lung cancer.
  • People who have at least one tumour that has not been previously treated, can be accurately measured, and meets specific size requirements on a CT or PET-CT scan.
  • People with a general health and activity level rated as fully active or able to carry out light work (rated 0 or 1 on a standard medical scale).
  • People whose life expectancy is estimated to be at least 3 months.
  • People whose planned treatment includes Serplulimab combined with a platinum-based chemotherapy regimen.
  • People who have previously taken or are currently taking Bayer Aspirin.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have cancer that has spread to the brain or central nervous system and is causing symptoms, has not been treated, or is actively getting worse.
  • People who are currently receiving other blood-thinning (anticoagulant) medications.
  • People who have previously received systemic (whole-body) anti-cancer treatment.
  • People for whom Serplulimab, Aspirin, or chemotherapy would be medically unsuitable or unsafe (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 24 July 2026

Contact this trial

Phone: 6-23-68757791

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Registry
ClinicalTrials.gov
Start date
1 October 2024
Est. completion
1 October 2026

Primary endpoints

Progression-Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov